Platelet BioGenesis, a biotech startup developing a method for producing life-saving platelets without the need for human donations, is proud to announce that they won second place in the national BioSciKin/Simcere Sino-U.S. Startup Competition in Life Science in Shanghai, China.
Platelet BioGenesis was invited to participate in the 2016 national competition following their first place finish in Boston earlier this year. They joined 3 other North American companies (1 from Canada and 2 from California) to compete alongside 8 other finalists from China. The conference spanned 3 days and, amongst many strong competitors, Platelet BioGenesis placed 2nd and received a cash prize.
“We are very proud to have done so well amongst so many strong competitors,” said Sven Karlsson, President of Platelet BioGenesis. “Our endeavor has generated a lot of interest in the sector. We are tackling a very ambitious challenge that will extend access to platelet transfusions to billions of people – it’s exciting to be recognized for that mission.”
“China is investing heavily in a strong biotechnology sector and it was incredible to see this growth first hand.” said Dr. Jonathan Thon, Assistant Professor at Brigham and Women’s Hospital and Harvard Medical School, and inventor of Platelet BioGenesis’ patented bioreactor. “Regenerative medicine is the future of healthcare, we’re proud to be leading the way.”
About Platelet BioGenesis
Platelet BioGenesis is a pre-clinical stage biotech company that was spun out of Harvard in 2014 to produce donor-independent human platelets from pluripotent stem cells Platelet BioGenesis has developed and patented a microfluidic bioreactor, and shown that functional platelets can be generated from human stem cell cultures at scale. The company was selected to participate in MassCONNECT (run by MassBio), was a 2014 MassChallenge Finalist, a 2016 BioSciKin business competition winner, and has received support from the Massachusetts Life Sciences Center, and the NIH.
Simcere is an emerging leader in developing, manufacturing and marketing of innovative medicines and branded generics in China. Simcere was the first Chinese chemical and biological drug company to list on the NYSE in 2007. In 2013, the company went private for strategic considerations. In 2015, Simcere’s translational medicine and innovative drug R&D platform was recognized as a State Key Laboratory by the National Ministry of Science and Technology. The company has been actively pursuing cross-border partnerships to bring global innovation to China. In Boston and New Jersey, Simcere now has two offices in the US for accelerating international business development.
BioSciKin (BSK) is an open platform in China for life science entrepreneurs and innovators. BSK focuses on three major healthcare areas: novel therapeutics, medical devices and mobile healthcare services, BSK is looking for partnership from all over the world for co-development of innovative approaches in precision medicine. In Nanjing, Shanghai and Tianjin, BSK has established 3 R&D-oriented incubation parks with advanced R&D facilities to provide entrepreneurs with customized service and support packages. For more information, please go to BSK’s official website: www.bioscikin.com
Contact: Platelet BioGenesis, Whitney Berry, (720) 509.9448 | email@example.com